3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Dermatologic
18
Thoracic
5
Genitourinary
4
Head & Neck
3
Gastrointestinal
3
Breast
2
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Endocrine
1
CNS
1
Conditions
Brain Neoplasms
6
Glioblastoma
4
Central Nervous System Neoplasms
3
Neuroblastoma
2
Neoplasms, Germ Cell and Embryonal
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Astrocytoma
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pinealoma
1
Pheochromocytoma
1
Interventions
Radiosurgery
22
Nivolumab
21
Ipilimumab
19
pembrolizumab
15
Temozolomide
11
dabrafenib
10
binimetinib
10
encorafenib
8
Cyclophosphamide
8
trametinib
7
Magnetic Resonance Spectroscopy
7
Bevacizumab
6
fludarabine
5
cobimetinib
5
Specimen Handling
5
CTLA-4 Antigen
5
fludarabine phosphate
3
aldesleukin
3
Vemurafenib
3
Thalidomide
3
Paclitaxel
3
Oxaliplatin
3
Interleukin-2
3
Gemcitabine
3
Drug Therapy
3
Carboplatin
3
130-nm albumin-bound paclitaxel
3
ulixertinib
2
tovorafenib
2
relatlimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Immunotherapy
×
CNS
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled